Bio CaRGOS: Capture and release gels for optimized storage of Cancer Biospecimens

生物标志物在患者的检测、诊断、管理和监测中发挥着核心作用 得了癌症分析灵敏度和重现性等因素对临床分析至关重要。 基于血浆的生物标志物在纵向监测和早期检测中的效用 疾病或复发。目前，生物标本的保存状态已经完成， 主要使用亚冷冻器技术，成本过高，在大多数情况下当然不实用， 场景很明显，目前缺乏在室内保存生物标本的技术。 温度长时间。因此，存在一个关键的未满足的临床需求， 大量的生物样本 在这里，我们建议证明胰腺癌特异性的稳定性和完整性， 生物标志物（CA-A19，miRNA 21和ctDNA）在缓冲液以及血浆中的延长时间， 在室温下放置一段时间。要实现这一目标，必须克服几个障碍。 由于其固有的复杂性质，直接稳定血浆中的生物标志物。拟议 技术是基于我们在开发CaRGOS方面的创新：捕获和释放凝胶， 优化生物样本的储存。拟议方法的技术影响是 一种肿瘤生物标本水溶液一步瞬时保存方法的实现 感兴趣的研究和临床样本。这项技术非常简单，用户 友好，消除了几个复杂的过程，更重要的是不需要大量的 设备.关键的科学影响包括我们对环境中的相互作用的基本见解。 生物标志物和其他蛋白质/溶质与二氧化硅前体。根据这一基本原则， 该方法可以容易地扩展到包括临床样品的其它研究领域， 抗原、生物制药、药物、病毒和细胞系。如果成功，创新 拟议的研究将导致癌症储存和保存的范式转变 目前技术无法实现的水性制剂中的生物标本。

Biomarkers play a central role in the detection, diagnosis, management and monitoring of patients with cancer. Factors such as analytical sensitivity and reproducibility are critical to the clinical utility of plasma based biomarkers in the setting of longitudinal surveillance and early detection of disease and or recurrence. Currently, the state of preservation of biospecimens is accomplished primarily using sub freezer techniques and it is cost prohibitive and certainly not practical in most scenarios. There is clearly a dearth of techniques that can preserve the biospecimens at room temperature for long periods of time. Therefore, there is a critical unmet clinical need for storing a plethora of biospecimens acquired routinely. Here, we propose to demonstrate stability and integrity of Pancreatic Cancer Specific biomarkers (CA-A19, miRNA21, and ctDNA) in buffers as well as plasma for extended periods of time at room temperature. There are several hurdles that must be overcome to realize the stabilization of biomarkers in plasma directly, due to its inherent complex nature. The proposed technology is based upon our innovation in developing CaRGOS: Capture and Release Gels for Optimized storage of Biospecimens. The technical impact of the proposed methodology is achievement of instantaneous one-step aqueous biospecimen preservative method for cancer research and clinical samples of interest. The proposed technology is extremely simple, user friendly, eliminates several complex processes, and more importantly requires no substantial equipment. The key scientific impact includes our fundamental insight into the interactions of the biomarkers and other proteins/solute with silica precursors. Based on this fundamental principle, the methodology can be easily expanded to other research areas including clinical samples, antigens, bio-pharmaceuticals, drugs, viruses and cell lines. If successful, the innovative proposed research will result in a paradigm shift in storage and preservation of Cancer Biospecimens in aqueous formulations that current techniques are unable to achieve.